Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) ( NSE:DRREDDY) (NYSE:RDY) announced on Monday the availability of Fulvestrant Injection in 250 mg/5 ml (50 mg/ml) persingle-dose syringe in the US market.

The company said the Fulvestrant Injection in 250 mg/5 ml (50 mg/ml) persingle-dose syringe is the therapeutic equivalent generic version of the US Food and Drug Administration (USFDA) approved Faslodex (fulvestrant) Injection in 250 mg/5 ml (50 mg/ml).

For the most recent 12 months ending in June 2020, the Faslodex brand and generic market had US sales of approximately USD407m MA, according to IQVIA Health.

According to the company, the Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe is available in a carton containing two 5 ml single-dose prefilled syringes.

Fulvestrant, sold under the brand name Faslodex, is a medication used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer, concluded the company.